Travere Therapeutics, Inc. TVTX

TVTX Company Overview

Travere Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on the development and commercialization of therapies for people living with rare diseases. The company operates within the biopharmaceutical and rare disease therapeutics industries, with a strategic emphasis on conditions with high unmet medical need and limited treatment options. Its core value proposition centers on advancing targeted, disease-modifying medicines supported by specialized commercial capabilities in rare and ultra-rare indications.

The company’s primary revenue driver is its approved and late-stage therapeutics portfolio, led by FILSPARI (sparsentan), a first-in-class dual endothelin and angiotensin receptor antagonist. Travere’s strategic positioning is based on deep expertise in rare renal and metabolic diseases, regulatory experience in orphan indications, and a focused commercial infrastructure. Founded in 2006 as Retrophin, Inc., the company rebranded as Travere Therapeutics in 2019 to reflect a broader mission of advancing transformative therapies, evolving from an acquisition-driven model to one centered on internal research, development, and commercialization.